• 1. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Recent Advances in the Study of 5-Fluoro-4-methyl-2-nitrobenzyl alcohol (CAS: 1803833-15-9) and Its Applications in Chemical Biology and Pharmaceutical Research

5-Fluoro-4-methyl-2-nitrobenzyl alcohol (CAS: 1803833-15-9) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery and development. Recent studies have highlighted its role as a versatile intermediate in the synthesis of bioactive molecules, particularly in the context of targeted drug delivery and photolabile protecting groups. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, mechanistic insights, and therapeutic potential.

A recent study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 5-Fluoro-4-methyl-2-nitrobenzyl alcohol, emphasizing its utility in the development of photoresponsive drug carriers. The researchers demonstrated that the nitrobenzyl moiety, when incorporated into prodrug designs, enables controlled release of active pharmaceutical ingredients (APIs) upon exposure to specific wavelengths of light. This property is particularly valuable in oncology, where localized drug activation can minimize systemic toxicity. The study also reported improved solubility and stability profiles of derivatives synthesized from this compound, further enhancing its appeal for pharmaceutical applications.

In another groundbreaking investigation, a team from the University of Cambridge utilized 5-Fluoro-4-methyl-2-nitrobenzyl alcohol as a key building block for the development of novel enzyme inhibitors. The fluorine substitution at the 5-position was found to significantly enhance binding affinity to target proteins, as evidenced by X-ray crystallography and molecular dynamics simulations. These findings were published in ACS Chemical Biology and have sparked renewed interest in the compound's potential for structure-based drug design, particularly in the treatment of neurodegenerative diseases.

The compound's mechanism of action has been further elucidated through recent computational studies. Density functional theory (DFT) calculations have provided insights into the electronic effects of the fluoro and nitro substituents, explaining the compound's unique reactivity patterns. These theoretical studies, combined with experimental data, suggest that 5-Fluoro-4-methyl-2-nitrobenzyl alcohol may serve as an excellent model system for understanding more complex nitroaromatic compounds in medicinal chemistry.

From a safety and pharmacokinetics perspective, recent preclinical evaluations have shown promising results. The compound exhibits favorable ADME (Absorption, Distribution, Metabolism, and Excretion) properties, with particular advantages in blood-brain barrier penetration. This characteristic makes it particularly valuable for CNS-targeted therapies. However, researchers caution that further toxicological studies are needed to fully assess its safety profile before clinical translation.

Looking forward, the scientific community anticipates several promising directions for research involving 5-Fluoro-4-methyl-2-nitrobenzyl alcohol. These include its potential application in PROTAC (Proteolysis Targeting Chimera) technology, where its structural features could facilitate the development of novel protein degraders. Additionally, its photolabile properties are being explored for applications in optopharmacology, a rapidly growing field that combines optics and pharmacology for precise control of drug activity.

In conclusion, 5-Fluoro-4-methyl-2-nitrobenzyl alcohol (CAS: 1803833-15-9) represents a compound of growing importance in chemical biology and pharmaceutical research. Its unique structural features, combined with recent advances in synthetic methodologies and mechanistic understanding, position it as a valuable tool for drug discovery and development. As research continues to uncover new applications and refine existing ones, this compound is likely to play an increasingly significant role in addressing current challenges in medicinal chemistry and therapeutic development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)